Cambridge Healthtech Institute’s 13th Annual

Advances in Drug Metabolism & Safety Testing

Optimizing Drug Metabolism; Predicting Drug Toxicity; Improving Translation into Clinic

June 2-4, 2020


Lead compounds in drug discovery need to be optimized for both efficacy and safety. Unfortunately, some of the adverse events related to metabolism, clearance, transport and drug-drug interactions do not surface until much later in development. Similarly, cardiotoxicity, hepatotoxicity and idiosyncratic drug toxicity continue to haunt the drug development process. While new screening technologies, in vitro assays, in vivo models and computational tools are being developed and used, scientists are still unclear about when, where and which tools to use, how reliable the data is, and how predictive the translation is from in vitro to in vivo. Cambridge Healthtech Institute’s Advances in Drug Metabolism & Safety Testing conference looks at the scientific and technological progress being made to optimize lead compounds and predict drug-induced toxicities early in drug discovery, and to better translate these findings to the clinic. The talks and discussions highlight relevant case studies, recent research findings, and the use of innovative assays and technologies for improving drug safety.

OPTIMIZING DRUG METABOLISM

The Impact of Intracellular Free Drug Concentration on Prediction of Clearance and Drug-Drug Interaction
Li Di, PhD, Research Fellow, Pharmacokinetics, Dynamics and Metabolism, Pfizer

Using DILIsym to Predict Hepatotoxicity Risk During Pre-Clinical Development
Paul Michalski, PhD, Investigator, Quantitative Systems Pharmacology, Glaxo Smith Kline

Local Metabolism Leads to Better Understanding of Tissue Drug Concentration for New Modalities
Donglu Zhang, PhD, Principal Scientist, Drug Metabolism and Pharmacokinetics, Genentech, Inc.

predicting DRUG TOXICITY

Off-Target Toxicity is a Common Mechanism of Action of Cancer Drugs Undergoing Clinical Trials
Jason Sheltzer, PhD, Principal Investigator, Cold Spring Harbor Laboratory

CRISPR Screens Identify Regulators of Antibody-Drug Conjugate Toxicity

Kimberly Tsui, PhD, Postdoctoral Fellow, Laboratory of Dr. Andrew Dillin, Department of Molecular and Cell Biology, University of California, Berkeley

 

ML and AI on ADME/Tox Accelerating Drug Discovery
Barun Bhhatarai, PhD, Investigator, Novartis Institute for Biomedical Research

Artificial Intelligence and Small-Molecule Drug Metabolism
Joshua Swamidass, MD, PhD, Assistant Professor, Immunology and Pathology, Laboratory and Genomic Medicine; Faculty Lead, Translational Informatics, Institute for Informatics, Washington University

improving IN VIVO translation

Challenges with Translation of in vitro Studies Using Human Derived Tissues
Gary Gintant, PhD, Senior Research Fellow, Department of Integrative Pharmacology, Integrated Science and Technology, AbbVie

“Tissues-on-Chips”: Innovative Approach to Preclinical Toxicity Testing on Human Tissue
Danilo A. Tagle, PhD, Associate Director for Special Initiatives, National Center for Advancing Translational Sciences, National Institutes of Health

Human-on-a-Chip Applications in ADME/Tox to Predict Clinical Outcomes
James Hickman, PhD, Founding Director, NanoScience Technology Center and Professor, Nanoscience Technology, Chemistry, Biomolecular Science, Material Science and Electrical Engineering, University of Central Florida

Human Heart Slices as a Reliable Platform for Predicting Cardiotoxicity
Tamer Mohamed, PhD, Assistant Professor of Medicine, Institute of Molecular Cardiology, University of Louisville

Update on the Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium Initiatives
Sarine Markossian, PhD, Specialist, Department of Pharmaceutical Chemistry, University of California San Francisco